Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Fujifilm Diosynth Biotechnologies

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Novavax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Partnership August 17, 2020

            Details:

            FUJIFILM's site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. Billingham plans to begin production of the first batch at beginning of Q1, 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 03, 2020

            Details:

            FUJIFILM Diosynth Biotechnologies' College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S Government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 27, 2020

            Details:

            FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase I Product Type: Vaccine

            Recipient: Novavax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 23, 2020

            Details:

            The Agreement aims to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Dr. Reddys Laboratories

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            Avigan (favipiravir) is an antiviral medication largely used to treat influenza in Japan. It was approved in the country in 2014 and became a generic drug in 2019.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Live modified horsepox virus vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2020

            Details:

            Under the agreement, Fujifilm Diosynth Biotechnologies will develop a manufacturing process, manufacture, and stock a supply of TNX-1800 at FDB’s College Station, Texas site for Tonix’s clinical development.